Indications for Intra Vitreal Bevacizumab (Avastin)

Abstract

Intra vitreal Injections are one of the modes of Ocular Drug delivery systems.  Anti VEGF agent, Inj. Ranibizumab (Lucentis) was approved for treatment of Wet ARMD to stabilize the Sub Retinal New vessels. A similar Drug Inj. Bevacizumab ( Avastin), approved for Colo Rectal Cancer is also being widely used for the same purpose all over the world as an off label drug.  In recent times, Inj. Bevacizumab (Avastin), has become very popular and being used in Various other Ocular  conditions. Bevacizumab is the predominant agent used to treat neovascular AMD worldwide [1] Since 2006, there have been reports of over fifty ocular entities being treated with Bevacizumab, generally those associated with Neovascularization or Vascular leakage as a consequence of an underlying disease [2]. This is a Retrospective study of the Data entered in Retina Dept of Government Tertiary care centre to show the changing pattern of usage of Inj. Bevacizumab (Avastin) in various conditions of the Eye between April 2014 - March 2015.

During Past one year the Indications were widening and Inj. Bevacizumab is being used and tried for some conditions which were not responding to other known treatment protocols.